The heterogeneous spectrum of the long QT syndrome

European Journal of Internal Medicine

Volumn 17, Issue 4, 2006, Pages 235-240

  Patel, Nehal D ^a   Singh, Binod K ^a   Mathew, Sunil T ^b  

^a STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Long QT syndrome; Sudden cardiac death; Ventricular arrhythmias

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; ANTIHISTAMINIC AGENT; ANTIINFECTIVE AGENT; ARSENIC TRIOXIDE; ASTEMIZOLE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUTYROPHENONE DERIVATIVE; CESIUM CHLORIDE; CISAPRIDE; CLARITHROMYCIN; COTRIMOXAZOLE; DISOPYRAMIDE; DOMPERIDONE; HALOFANTRINE; KETOCONAZOLE; MACROLIDE; MEFLOQUINE; PAPAVERINE; PENTAMIDINE; PHENOTHIAZINE DERIVATIVE; POTASSIUM CHANNEL; PROCAINAMIDE; PSYCHOTROPIC AGENT; QUINIDINE; SODIUM CHANNEL; SOTALOL; TERFENADINE; THIORIDAZINE; UNINDEXED DRUG;

ACTION POTENTIAL; BETA ADRENERGIC RECEPTOR BLOCKING; BRADYCARDIA; CARDIOVASCULAR DISEASE; CELL MEMBRANE; DEATH; DEFIBRILLATOR; ELECTROCARDIOGRAM; EMOTIONAL STRESS; GENE MAPPING; GENE MUTATION; GENETIC IDENTIFICATION; GENETIC LINKAGE; GENOTYPE; HEART MUSCLE CELL; HEART RATE; HEART VENTRICLE ARRHYTHMIA; HUMAN; LIFESTYLE; LONG QT SYNDROME; NONHUMAN; PROGNOSIS; PUERPERIUM; QT INTERVAL; REVIEW; RISK ASSESSMENT; SUDDEN DEATH; TORSADE DES POINTES;

EID: 33744524564     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejim.2005.12.001     Document Type: Review

References (60)

1. Priori S.G., Barhanin J., Hauer R.N.W., Haverkamp W., Jongsma H.J., Kleber A.G., et al. Genetic and molecular basis of cardiac arrhythmias: impact on clinical management: Parts I and II. Circulation 99 (1999) 518-528
2. Romano C., Gemme G., and Pongiglione R. Aritme cardiache rare dell'eta pediatrica. Clin Pediatr 45 (1963) 656-683
3. Ward O.C. A new familial cardiac syndrome in children. J Ir Med Assoc 54 (1964) 103-106
4. Jervell A., and Lange-Nielsen F. Congenital deaf-mutism, functional heart disease with prolongation of the QT interval, and sudden death. Am Heart J 54 (1957) 59-68
5. Moss A.J., Schwartz P.J., Crampton R.S., Locati E., and Carleen E. The long QT syndrome: a prospective international study. Circulation 71 No. 1 (1985) 17-21
6. Wehrens X.H.T., Vos M.A., Doevendans P.A., and Wellens H.J.J. Novel insights in the congenital long QT syndrome. Ann Intern Med 137 (2002) 981-992
7. Geelen J.L., Doevendans P.A., Jongbloed R.J., Wellens H.J., and Geraedts J.P. Molecular genetics of inherited long QT syndromes. Eur Heart J 19 (1998) 1427-1433
8. Vincent G.M., Timothy K.W., Leppert M., and Keating M. The spectrum of symptoms and QT intervals in carriers of the gene for the long QT syndrome. N Engl J Med 327 (1992) 846-852
9. Moss A.J., Robinson J.L., Gessman L., Gillespie R., Zareba W., Schwartz P.J., et al. Comparison of clinical and genetic variables of cardiac events associated with loud noise vs. swimming among subjects with the long QT syndrome. Am J Cardiol 84 (1999) 876-879
10. Shimizu W., and Antzelevitch C. Cellular basis for the ECG features of the long QT syndrome: effects of beta-adrenergic agonists and antagonists and sodium channel blockers on transmural dispersion of repolarization and torsade de pointes. Circulation 98 (1998) 2314-2322
11. Van Den Berg M.P., Wilde A.A., Viersma T.J., Brouwer J., Haaksma J., van der Hout A.H., et al. Possible bradycardiac mode of death and successful pacemaker treatment in a large family with features of long QT syndrome type 3 and Brugada syndrome. J Cardiovasc Electrophysiol 12 (2001) 630-636
12. Maron B.J., Moller J.H., Seidman C.E., Vincent G.M., Dietz H.C., Moss A.J., et al. Impact of laboratory molecular diagnosis on contemporary diagnostic criteria for genetically transmitted cardiovascular diseases: hypertrophic cardiomyopathy, long QT syndrome, and Marfan syndrome. Circulation 98 (1998) 1460-1471
13. Schwartz P.J., Moss A.J., Vincent G.M., and Crampton R.S. Diagnostic criteria for the long QT syndrome: an update. Circulation 88 (1993) 782-784
14. Maron B.J., Moller J.H., Seidman C.E., Vincent G.M., Dietz H.C., Moss A.J., et al. Impact of laboratory molecular diagnosis on contemporary diagnostic criteria for genetically transmitted cardiovascular diseases: hypertrophic cardiomyopathy, long QT syndrome, and Marfan syndrome. Circulation 98 (1998) 1460-1471
15. Schwartz P., Locati E., Napolitano C., and Priori S. The long QT syndrome. In: Zipes D., and Jalife J. (Eds). Cardiac electrophysiology: from cell to bedside (1995), WB Saunders, Philadelphia 788
16. Schwartz P.J., and Locati E. The idiopathic long QT syndrome: pathogenetic mechanisms and therapy. Eur Heart J 6 Suppl. D (1985) 103-114
17. Garson A., Dick M., and Fournier A. The long QT syndrome in children: an international study of 287 patients. Circulation 87 (1993) 1866
18. Lehmann M.H., Timothy K.W., Frankovich D., Fromm B., Keating M., Locati E.H., et al. Age-gender influence on the rate-corrected QT interval and the QT-heart rate relation in families with genotypically characterized long QT syndrome. J Am Coll Cardiol 29 (1997) 93-99
19. Priori S.G., Schwartz P.J., Napolitano C., Bloise R., Ronchetti E., Grillo M., et al. Risk stratification in the long QT syndrome. N Engl J Med 348 (2003) 1866-1874
20. Rashba E.J., Zareba W., Moss A.J., Hall W.J., Robinson J., Locati E.H., et al. Influence of pregnancy on the risk for cardiac events in patients with hereditary long QT syndrome. LQTS Investigators. Circulation 97 (1998) 451-456
21. Schwartz P.J., Periti M., and Malliani A. The long QT syndrome. Am Heart J 89 (1975) 378-390
22. Pham T.V., Sosunov E.A., Gainullin R.Z., Danilo Jr. P., and Rosen M.R. Impact of sex and gonadal steroids on prolongation of ventricular repolarization and arrhythmias induced by I(K)-blocking drugs. Circulation 103 (2001) 2207-2212
23. Tanabe S., Hata T., and Hiraoka M. Effects of estrogen on action potential and membrane currents in guinea pig ventricular myocytes. Am J Physiol 277 (1999) H826-H833
24. Jackman W., Friday K., and Anderson J. The long QT syndromes: a critical review, new clinical observations, and a unifying hypothesis. Prog Cardiovasc Dis 31 (1988) 115
25. Wilde A.A., Jongblood R.J., Doevendans P.A., Duren D.R., Hauer R.N., van Langen I.M., et al. Auditory stimuli as a trigger for arrhythmic events differentiate HERG-related (LQTS2) patients from KvLQT1-related patients (LQTS1). J Am Coll Cardiol 33 (1999) 327-332
26. Schwartz P.J., Priori S.G., Spazzolini C., Moss A.J., Vincent G.M., Napolitano C., et al. Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation 103 (2001) 89-95
27. Wellens H.J., Vermeulen A., and Durrer D. Ventricular fibrillation occurring on arousal from sleep by auditory stimuli. Circulation 46 (1972) 661-665
28. Nakajima T., Misu K., Iwasawa K., Tamiya E., Segawa K., Matsuo H., et al. Auditory stimuli as a major cause of syncope in a patient with idiopathic long QT syndrome. Jpn Circ J 59 (1995) 241-246
29. Haverkamp W., Breithardt G., Camm A.J., Janse M.J., Rosen M.R., Antzelevitch C., et al., and other speakers in the sessions and the chairs of the workshops. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Eur Heart J 21 (2000) 1216-1231
30. Sesti F., Abbott G.W., Wei J., Murray K.T., Saksena S., Schwartz P.J., et al. A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proc Natl Acad Sci U S A 97 (2000) 10613-10618
31. Kr potassium channels with HERG and is associated with cardiac arrhythmia. Cell 97 (1999) 175-187
32. Napolitano C., Schwartz P.J., Brown A.M., Ronchetti E., Bianchi L., Pinnavaia A., et al. Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias. J Cardiovasc Electrophyiol 11 (2000) 691-696
33. Wei J., Abbott G.W., Sesti F., Goldstein S.A., Schwartz P.J., Saksena S., et al. Prevalence of KCNE2 (MiRP1) mutations in acquired long QT syndrome. Circulation 100 18S (1999) I495 [Abstract]
34. Donger C., Denjoy I., Berthet M., Neyroud N., Cruaud C., Bennaceur M., et al. KVLQT1 C-terminal missense mutation causes a forme-fruste long-QT syndrome. Circulation 96 (1997) 2778-2781
35. Priori S.G., Aliot E., Blomstrom-Lundqvist C., Bossaert L., Breithardt G., Brugada P., et al. Task force on sudden cardiac death of the European Society of Cardiology. Eur Heart J 22 (2001) 1374-1450
36. Zimetbaurn P., and Josephson M.E. Prognosis and management of the long QT syndrome and torsade de pointe. Up To Date (2003) 1-25 [Version 11.2]
37. Moss A.J., Zareba W., Hall W.J., Schwartz P.J., Crampton R.S., Benhorin J., et al. Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome. Circulation 101 (2000) 616-623
38. Silka M.J., Kron J., Dunnigan A., and Dick II M. Sudden cardiac death and the use of implantable cardioverter-defibrillators in pediatric patients. The Pediatric Electrophysiology Society. Circulation 87 (1993) 800-807
39. Groh W.J., Silka M.J., Oliver R.P., Halpern B.D., McAnulty J.H., and Kron J. Use of implantable cardioverter-defibrillators in the congenital long QT syndrome. Am J Cardiol 78 (1996) 703-706
40. Dorostkar P.C., Eldar M., Belhassen B., and Scheinman M.M. Long-term follow-up of patients with long-QT syndrome treated with beta-blockers and continuous pacing. Circulation 100 (1999) 2431-2436
41. Wilde A.A., and Roden D.M. Predicting the long-QT genotype from clinical data: from sense to science. Circulation 102 (2000) 2796
42. Shimizu W., and Antzelevitch C. Differential effects of beta-adrenergic agonists and antagonists in LQT1, LQT2, and LQT3 models of the long QT syndrome. J Am Coll Cardiol 35 (2000) 778
43. Brachman J., Scherlag B.J., Rosenshtraukh L.V., and Lazzara R. Bradycardia-dependent triggered activity: relevance to drug-induced multiform ventricular tachycardia. Circulation 68 (1983) 846-856
44. Cranefield P.F., and Aronson R.S. Torsade de pointe and other pause-induced ventricular tachycardias: the short-long-short sequence and early after-depolarizations. Pacing Clin Electrophysiol 11 (1988) 670-678
45. Ratskin R.A., Hunt D., Russell Jr. R.O., and Rackley C.E. QT interval prolongation, paroxysmal ventricular arrhythmias, and convulsive syncope. Ann Intern Med 75 (1971) 919-924
46. Roy P.R., Emanuel R., Ismail S.A., and El Tayib M.H. Hereditary prolongation of the QT interval. Genetic observations and management in three families with twelve affected members. Am J Cardiol 37 (1976) 237-243
47. DiSegni E., David D., Katzenstein M., Klein H.O., Kaplinsky E., and Levy M.J. Permanent overdrive pacing for the suppression of recurrent ventricular tachycardia in a newborn with long QT syndrome. J Electrocardiol 13 (1980) 189-192
48. Medina-Ravellv, Castellanos A., Portillo-Acosta B., Maduro-Maytin C., Rodriguez-Salas L., Hernandez-Arenas M., et al. Management of tachyarrhythmias with dual-chamber pacemakers. Pacing Clin Electrophysiol 6 (1983) 333-345
49. Wilmer C.I., Stein B., and Morris D.C. Atrioventricular pacemaker placement in Romano-Ward syndrome and recurrent torsade de pointe. Am J Cardiol 59 (1987) 171-172
50. Scott W.A., and Dick II M. Two : one atrioventricular block in infants with congenital LQTS. Am J Cardiol 60 (1987) 1409-1410
51. Viskin S. Cardiac pacing in the long QT syndrome: review of available data and practical recommendations. J Cardiovasc Electrophysiol 11 (2000) 593-600
52. Benhorin J., Taub R., Goldmit M., Kerem B., Kass R.S., Windman I., et al. Effects of flecainide in patients with new SCN5A mutation: mutation-specific therapy for long-QT syndrome?. Circulation 101 (2000) 1698-1706
53. + channel blockade and to increases in heart rate. Implications for gene-specific therapy. Circulation 92 (1995) 3381-3386
54. Compton S.J., Lux R.L., Ramsey M.R., Strelich K.R., Sanguinetti M.C., Green L.S., et al. Genetically defined therapy of inherited long-QT syndrome. Circulation 94 (1996) 1018-1023
55. Shimizu W., Kurita T., Matsuo K., Suyama K., Aihara N., Kamakura S., et al. Improvement of repolarization abnormalities by a K channel opener in the LQT1 form of congenital long QT syndrome. Circulation 97 (1998) 1581-1588
56. Berul C.I., Seslar S.P., Zimetbaum P., and Josephson M.E. Acquired long QT syndrome. In: Rose B.D. (Ed). UpToDate (2005), UpToDate, Waltham (MA)
57. Drici M.D., and Clement N. Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome. Drug Safety 24 8 (2001) 575-585
58. Hara M., Danilo Jr. P., and Rosen M.R. Effects of gonadal steroids in ventricular repolarization and on the response to E4031. J Pharmacol Exp Ther 285 (1998) 1068-1072
59. Laham R.J., and Simons M. New medical and invasive therapies for angina pectoris. In: Rose B.D. (Ed). UpToDate (2005), UpToDate, Waltham (MA)
60. (f) inhibitor, in stable angina, a randomized, double-blind, multicentered, placebo-controlled trial. Circulation 107 6 (2003) 817-823